5 amino 1 Mq

Beschrijving

5-Amino-1MQ (5-amino-1-methylquinolinium) is an investigational small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in NAD+ metabolism and energy regulation. By selectively blocking NNMT activity, 5-Amino-1MQ reduces the methylation of nicotinamide, preserving NAD+ pools and enhancing the activity of sirtuins (particularly SIRT1, often called the “longevity gene”). This mechanism boosts mitochondrial function, increases cellular energy expenditure, promotes fat oxidation (especially in adipose tissue), inhibits lipogenesis, and supports improved insulin sensitivity and metabolic health. Preclinical studies in high-fat diet-induced obese mice demonstrate significant weight loss, reduced adipose tissue mass, preserved lean mass, enhanced muscle strength and endurance (in aged models), and reversal of obesity-related metabolic dysfunction without major toxicity at tested doses. These effects mimic aspects of caloric restriction or exercise, making 5-Amino-1MQ a candidate for obesity management, age-related sarcopenia, and metabolic disorders. In wellness, anti-aging, and performance communities, 5-Amino-1MQ is often used orally (capsules typically 50mg or 500mcg per dose, with anecdotal/research ranges of 50–300mg daily) or in compounded forms to support fat reduction, muscle preservation during calorie deficits, increased vitality, better recovery, and potential synergy with NAD+ therapies or other longevity compounds. Users report gradual improvements in energy, body composition, and metabolic markers over weeks to months when combined with proper nutrition and training. While preclinical data is promising and early human anecdotal evidence suggests a favorable profile with minimal reported side effects (mild gastrointestinal upset, headache, or appetite changes in some cases), 5-Amino-1MQ is not FDA-approved for any therapeutic, weight loss, anti-aging, or medical use as of 2026—no large-scale human clinical trials have been completed to confirm long-term efficacy, optimal dosing, or safety. Evidence relies on animal models, mechanistic studies, and widespread user reports rather than rigorous randomized controlled trials in people. Potential risks include unknown long-term metabolic impacts, interactions with medications affecting NAD+ pathways, or off-target effects—though animal toxicity appears low at relevant doses. Always use under supervision from a qualified healthcare provider experienced in metabolic or peptide therapies, with monitoring of labs (glucose, lipids, liver function) and proper sourcing from reputable compounding pharmacies. 5-Amino-1MQ should complement—not replace—evidence-based lifestyle interventions like diet, exercise, and sleep for metabolic health or body composition goals. Consult a professional to assess suitability and stay updated on emerging research or regulatory developments.